The Ensign Group (ENSG)
(Delayed Data from NSDQ)
$148.43 USD
-0.61 (-0.41%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $148.38 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$148.43 USD
-0.61 (-0.41%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $148.38 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum B VGM
Zacks News
Bruker (BRKR) Q3 Earnings and Revenues Top, '23 Sales View Up
by Zacks Equity Research
Bruker (BRKR) delivers better-than-expected earnings and revenues in the third quarter of 2023.
Prestige Consumer (PBH) Q2 Revenues Top, Margins Expand
by Zacks Equity Research
Prestige Consumer's (PBH) second-quarter fiscal 2024 results benefit from a diverse brand portfolio and broad distribution.
Omnicell (OMCL) Q3 Earnings and Revenues Beat, Margins Down
by Zacks Equity Research
Omnicell's (OMCL) third-quarter 2023 results reflect operational discipline in a weak demand environment.
Cigna (CI) Q3 Earnings Beat on Membership Growth, '23 EPS View Up
by Zacks Equity Research
Cigna's (CI) Q3 results benefit on well-performing U.S. Commercial and Medicare Advantage businesses. Management currently expects 2023 adjusted EPS to be a minimum of $24.75.
Tandem Diabetes (TNDM) Posts Wider Q3 Loss, Trims '23 Sales View
by Zacks Equity Research
Tandem Diabetes (TNDM) reports a higher-than-anticipated loss in the third quarter of 2023.
Ensign Group (ENSG) Q3 Earnings Beat on Occupancy, Stock Up 2.4%
by Zacks Equity Research
Ensign Group's (ENSG) third-quarter results benefit on solid segmental contribution and occupancy strength. Management currently expects adjusted EPS to be within $4.73-$4.79 for 2023.
Can Stocks Enjoy Halloween Effect Despite Rising Rate Fear?
by Sanghamitra Saha
The spooky occasion Halloween can turn into an occasion of angels for Wall Street. Top-ranked sectors like energy, construction, medical and utilities, especially, have the potential to experience a Halloween Effect this year.
Ensign Group (ENSG) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Ensign Group (ENSG) delivered earnings and revenue surprises of 1.69% and 0.20%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Ensign Group (ENSG) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
UnitedHealth Group's (UNH) Arm OptumRx Expands in Arizona
by Zacks Equity Research
UnitedHealth Group (UNH) is set to enhance the offerings of OptumRx with the recent expansion of pharmacy care services in Arizona.
Centene (CNC) Eyes Membership Growth With 2024 Expansion Plans
by Zacks Equity Research
Centene (CNC) declares the availability of a varied set of health plans across new counties in 2024. It, thereby, places intensified focus on growing its Medicare business.
Ensign (ENSG) Buys Providence Place Nursing Facility in Kansas
by Zacks Equity Research
The Providence Place deal increases Ensign's (ENSG) portfolio to encompass 296 healthcare operations, spanning 13 states.
Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now
by Zacks Equity Research
Growing Membership, expanding government business, strategic acquisitions, improving operating margin and solid 2024 plans poise UnitedHealth Group (UNH) well for growth.
Here's Why Investors Should Retain Humana (HUM) Stock Now
by Zacks Equity Research
Humana (HUM) benefits from an upgraded health plan offering suite, expanding Medicare Advantage membership and solid cash reserves.
Here's Why Ensign Group (ENSG) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
UnitedHealth Group (UNH) to Expand Coverage Area in 2024
by Zacks Equity Research
UnitedHealth Group (UNH) is set to enhance its offerings with UCard and expand to 110 new counties in 2024 with its Individual Medicare Advantage Plan.
Why Ensign Group (ENSG) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Here's Why Ensign Group (ENSG) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Ensign Group (ENSG) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Ensign Group (ENSG) Pursues Facility Buyouts in South Carolina
by Zacks Equity Research
Ensign Group (ENSG) acquires two skilled nursing facilities in South Carolina to offer enhanced healthcare services to the state's residents.
Humana (HUM) to Provide In-home Care With Primary Care Anywhere
by Zacks Equity Research
Humana (HUM) enhances its CenterWell brand with the launch of Primary Care Anywhere.
Centene (CNC) Divests Circle Health Group, Optimizes Portfolio
by Zacks Equity Research
Centene (CNC) announces the sale of Circle Health Group to PureHealth in a bid to dispose of non-core assets and grow its core Managed Care business.
Humana (HUM) to Bring Enhanced Kidney Care to MA Members
by Zacks Equity Research
Humana (HUM) makes Interwell's extensive resources available to its MA members grappling with CKD and ESKD, and hence bring about better health outcomes for them.